文献速递流行病学与生物统计真实世界研究与卫生经济

间接比较中使用真实世界对照的可识别性与选择偏倚:方法与报告的系统综述

Identifiability and selection bias in indirect comparisons using real-world controls: a systematic review of methods and reporting.
PubMed 文献 · J Clin Epidemiol · 2026-05-04

该系统综述评估了55项单臂药物试验使用真实世界对照进行间接比较时的方法学报告质量,其中29项采用平衡方法、26项采用其他方法。过半研究为肿瘤领域,仅29%提供了使用间接比较的理由。平衡方法组样本量更大、参与中心更多、发表时间更近,但调整后平衡评估常仅基于P值。

要点

  • 仅29%的单臂试验间接比较研究提供了使用真实世界数据的理由。
  • 真实世界对照患者的招募时间更长且更早,影响阳性假设。
  • 平衡方法组调整后平衡评估报告更频繁,但常仅基于P值。

核心结论

  • 为确保使用真实世界对照的非锚定间接比较的有效性,未来研究应采用并透明报告基于因果推断原则的稳健方法学框架。

研究设计与样本

  • 系统综述纳入1987年至2024年发表的55项单臂药物试验,比较采用平衡基础方法(29项)与其他方法(26项)的研究。

主要发现

  • 过半试验为肿瘤领域,血液肿瘤最常见。
  • 仅29%的研究提供了使用单臂试验与真实世界数据间接比较的理由。
  • 真实世界对照患者招募时间更长且更早,损害阳性假设。
  • 平衡方法组发表时间中位数2023年 vs 2019年,间接比较常紧随试验先前发表(66% vs 8%)。
  • 平衡方法组实验组样本量中位数77 vs 31,对照组97 vs 40,参与中心更多(单中心研究30% vs 57%)。

关键数值与推荐

  • 平衡方法组调整后平衡评估报告更频繁,但常仅基于P值(34% vs 62%)。
  • 使用加权方法的研究调整后平衡评估优于匹配方法。

临床怎么用

  • 使用真实世界对照进行间接比较时,应明确提供方法学理由并采用平衡基础方法控制混杂。
  • 应报告调整后平衡评估,避免仅依赖P值判断平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Recently, the integration of external controls to construct an externally controlled trial has gained attraction as a way to strengthen the level of evidence of single-arm trials (SATs). We aimed to systematically evaluate the reporting of key methodological features of indirect comparisons that use real-world (RW) controls to supplement single-arm drug trials. STUDY DESIGN AND SETTING: We conducted a systematic review to critically appraise the methodological features of these designs and identify key omissions. We compared studies based on methods that address selection bias by targeting covariate balance (eg, matching, weighting, g-computation, or doubly robust estimators) ("balancing-based methods"), with those which do not explicitly target imbalances, using outcome regression or unadjusted analyses for group adjustment ("other methods"). RESULTS: Our search identified 55 single-arm drug trials published from 1987 to 2024. Of these, 29 were described as using balancing-based methods and 26 used other methods. Over half of the trials were in oncology, with hematologic-oncology being the most represented pathology. Only 29% of studies provided a rationale for using an indirect comparison of the SAT to real-world data (RWD). RW control patients were recruited over longer and earlier time periods than patients in the SAT, compromising positivity assumption. Balancing-based methods were more recent compared to other methods (median of publication time, 2023 vs 2019), with the indirect comparison often following a previous publication of the trial (66% vs 8%). In the balancing-based group, sample sizes in both the experimental (median 77 vs 31) and control (median 97 vs 40) groups were higher, as well as the number of participating centers (with monocentric studies in 30% vs 57%). Assessment of postadjustment balance was reported more frequently in the balancing-based group, though often only based on P values (34% vs 62%), improved for those using weighting compared to matching approaches. CONCLUSION: To ensure the validity of unanchored indirect comparisons with RWD controls, future studies should adopt and transparently report on robust methodological frameworks based on the principles of causal inference. PLAIN LANGUAGE SUMMARY: Some drug trials do not include a comparison group ("single-arm trials [SATs]"), making it difficult to judge how well a treatment works in comparison to the standard of care (SoC) at the time. An increasingly popular solution is to compare patients in the SAT with similar patients identified from data collected outside of the clinical trial setting (such as medical records, administrative claims, and registries), also called "real-world data" (RWD). However, these observational data are of lower quality, lacks important information. Moreover, an indirect comparison of these two data sources (single-arm and real-world [RW]) requires adequate statistical analysis methods to avoid biased results. Our goal was to evaluate the clarity of reporting and the rigor of the analyses in these published comparisons. We evaluated a total of 55 studies published from 1987 to 2024. Most studies were in the field of oncology. Fewer than one-third of the studies explained why they chose to use RWD instead of trial data. RW control patients were recruited over longer and earlier time periods than patients in the SAT. The sample sizes in both the treated and control groups were larger, the groups were more balanced when the studies used recent statistical methods to control for systematic differences between them. Overall, our findings suggest that these studies do not report all the elements necessary to conclude that their findings are clinically relevant or reproducible.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Diouf M, Lambert J, Chevret S, et al. Identifiability and selection bias in indirect comparisons using real-world controls: a systematic review of methods and reporting. J Clin Epidemiol. 2026. PMID: 42092600. doi:10.1016/j.jclinepi.2026.112301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。